However, previous research showed that a single TIGIT blockade had no real benefit in CT26 tumor models while combination therapy with the PD-1/PD-L1 blockade resulted in complete tumor rejection through augmenting of CD8+ T cells proliferation and function (Johnston et al., 2014). The gene discussed is CD8A; the disease is neoplasm.